Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Lyashchenko

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.
The Lancet. Oncology|July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trialSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PETSimone Krebs, Darren R Veach, Lukas M Carter, et al.
Radiology|February 2, 2018
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of <sup>18</sup>F-(2S,4R)-4-FluoroglutamineMark P S Dunphy, James J Harding, Sriram Venneti, et al.
Neuro-Oncology Advances|January 4, 2021
Preclinical and first-in-human-brain-cancer applications of [<sup>18</sup>F]poly (ADP-ribose) polymerase inhibitor PET/MRRobert J Young, Paula Demétrio De Souza França, Giacomo Pirovano, et al.
Journal of Hematology & Oncology|November 12, 2022
Phase 1 study of intraventricular <sup>131</sup>I-omburtamab targeting B7H3 (CD276)-expressing CNS malignanciesKim Kramer, Neeta Pandit-Taskar, Brian H Kushner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
First-in-Human Trial of Epichaperome-Targeted PET in Patients with CancerMark P S Dunphy, Christina Pressl, Nagavarakishore Pillarsetty, et al.
Pediatric Blood & Cancer|September 24, 2017
A phase II study of radioimmunotherapy with intraventricular <sup>131</sup> I-3F8 for medulloblastomaKim Kramer, Neeta Pandit-Taskar, John L Humm, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.
The Lancet. Oncology|July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trialSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PETSimone Krebs, Darren R Veach, Lukas M Carter, et al.
Radiology|February 2, 2018
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of <sup>18</sup>F-(2S,4R)-4-FluoroglutamineMark P S Dunphy, James J Harding, Sriram Venneti, et al.
Neuro-Oncology Advances|January 4, 2021
Preclinical and first-in-human-brain-cancer applications of [<sup>18</sup>F]poly (ADP-ribose) polymerase inhibitor PET/MRRobert J Young, Paula Demétrio De Souza França, Giacomo Pirovano, et al.
Journal of Hematology & Oncology|November 12, 2022
Phase 1 study of intraventricular <sup>131</sup>I-omburtamab targeting B7H3 (CD276)-expressing CNS malignanciesKim Kramer, Neeta Pandit-Taskar, Brian H Kushner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
First-in-Human Trial of Epichaperome-Targeted PET in Patients with CancerMark P S Dunphy, Christina Pressl, Nagavarakishore Pillarsetty, et al.
Pediatric Blood & Cancer|September 24, 2017
A phase II study of radioimmunotherapy with intraventricular <sup>131</sup> I-3F8 for medulloblastomaKim Kramer, Neeta Pandit-Taskar, John L Humm, et al.
Pageof 8